Paras Biopharmaceuticals

What Paras Biopharmaceuticals does

Paras Biopharmaceuticals Finland Oy is a privately-held Finnish biopharmaceutical company founded in 2012 and headquartered in Oulu, operating a 25,000 ft2 microbial biologics production facility with a 4,300 ft2 classified cleanroom (BL1/BL2) and bioreactor capacity at 10L, 150L, and 750L scales. The company specializes in recombinant therapeutic protein and peptide production using proprietary E. coli expression technologies — Diabrid®, NobleCleav®, Biomultifold®, and Cytofold StructQuant® — which enable multigram-per-liter yields, efficient processing of complex biologics, and cytoplasmic folding of disulfide-rich proteins without requiring eukaryotic systems.

The business operates as a dual-divison enterprise. The Paras Biopharma division provides contract development and manufacturing (CDMO) services for biopharma customers in the USA and Europe, with engagement through direct enterprise sales, industry events (BIO, CPHI, BIO Europe, LSX), and partnering meetings. The Paras Biologics division develops and out-licenses a biosimilar pipeline — Teriparatide (Terishield™), Anakinra (IL-K™), Insulin Aspart (Asplin™), Romiplostim (Romi-MultiPlat™), Rasburicase (Raspa™), and Certolizumab (Ceras-Peg™) — targeting osteoporosis, rheumatoid arthritis, diabetes, and oncology, plus novel biologics/biobetters in multiple myeloma and osteoarthritis. A third revenue stream sells recombinant bioprocess enzymes (RapidTEV®, RapidEK®, RapidZymo®) via request-for-quote, distributed through the PSL Alliance and other channels.

Revenue is generated through project-based CDMO contracts, biosimilar co-development and licensing partnerships (notably a 2015 Novozymes VELTIS collaboration on a once-weekly Teriparatide biobetter), and unit-priced enzyme sales. The company is described as revenue-generating and profit-making, has deployed over €6 million in facility and analytical upgrades, secured a multi-million-euro investment from UK-based ASAP Growth Ltd in 2016, and is exploring a reverse merger to unlock value from its pipeline and CDMO capabilities.

Name

Paras Biopharmaceuticals

Legal name

Paras Biopharmaceuticals Finland Oy

Website

https://parasbiopharma.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Paras Biopharmaceuticals is a Finnish microbial biologics CDMO and biosimilar developer using proprietary E. coli expression technologies to serve biopharma companies in the USA and Europe with contract manufacturing, biosimilar co-development, and recombinant bioprocess enzymes.

Ownership category

akta.pro rank

Product category

Biologics Contract Development & Manufacturing (CDMO)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI), Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI), Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)

Keywords

• Microbial biologics CDMO
• Recombinant protein expression
• Biosimilar development services
• Bioprocess enzymes supply
• Plasmid DNA services

Headquarters

HQ city

Oulu

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Services (Contract Development & Manufacturing): Paras Biopharmaceuticals provides contract development and manufacturing services for recombinant biologics in microbial systems (E. coli). The company offers small scale (10L), medium scale (150L) and large scale (750L or more) production services. Revenue is generated through project-based contracts with biopharma companies in the USA and Europe. Services include process development, scale-up, and production of recombinant therapeutic products.
2. Biosimilar Development & Licensing: Paras develops biosimilar candidates (Teriparatide, Anakinra, Insulin Aspart, Romiplostim, Rasburicase, Certolizumab) using its proprietary technology platform and offers clinical development and marketing collaboration/partnership to pharmaceutical companies. Revenue comes from licensing deals, co-development partnerships, and milestone payments.
3. Recombinant Bioprocess Enzymes Sales: Paras sells recombinant bioprocess enzymes including RapidEK® (Enterokinase) and RapidTEV® Protease in various unit sizes (20, 100, 250, 1000, 10000 units). Products are sold via a request-for-quote model for biopharma R&D and production needs. Bulk sales enquiries are handled through the sales email.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Paras Biopharmaceuticals operates a contract development and manufacturing organization (CDMO) for recombinant biologics in microbial (E. coli) expression systems, offering process development and production at 10L, 150L, and 750L+ scales. The company also develops its own pipeline of biosimilar candidates (Teriparatide, Anakinra, Insulin Aspart, Romiplostim, Rasburicase, Certolizumab) and recombinant bioprocess enzymes (RapidEK®, RapidTEV®, RapidZymo®), leveraging four proprietary technology platforms: Diabrid®, NobleCleav®, Biomultifold®, and Cytofold StructQuant®.

Product overview

Paras Biopharmaceuticals Finland Oy operates a dual-divison business model: Paras Biopharma (CDMO) provides contract development and manufacturing services for recombinant biologics in microbial systems, while Paras Biologics manages the company's biosimilar and novel biologics pipeline. The core proprietary technology platform comprises four integrated technologies — Diabrid®, NobleCleav®, Biomultifold®, and Cytofold StructQuant® — which enable high-level expression and efficient processing of recombinant therapeutic proteins and peptides in E. coli, reducing production costs. The biosimilar pipeline includes five named products (Terishield™, IL-K™, Asplin™, Romi-MultiPlat™, Raspa™) targeting osteoporosis, rheumatoid arthritis, diabetes, and oncology, with a novel biologics program for rare/orphan diseases. The bioprocess enzymes portfolio (RapidTEV™, RapidEK™, RapidZymo®) serves the cleavage of fusion proteins and tags in biologics R&D and production.

Differentiator

Problem solved

Functional benefit

Brands

• Diabrid® Technology: Proprietary technology for the expression of recombinant therapeutic proteins and therapeutic peptides that enhances quality and bio-effectiveness while facilitating post-production protocols.
• NobleCleav® Technology
• Biomultifold® Technology
• Cytofold StructQuant® Technology
• RapidEK® (Recombinant Enterokinase)
• RapidTEV® Protease
• RapidZymo® (Recombinant Zymolyase)
• Terishield™ (Teriparatide)
• IL-KTM™ (Anakinra)
• Aspart™ (Insulin Aspart)
• Romi-MultiPlat™ (Romiplostim)
• Raspa™ (Rasburicase)
• Ceras-Peg™ (Certolizumab)

Products and services

• Paras Biopharma – Microbial Biologics CDMO
• Plasmid DNA Services
• Terishield™ (Teriparatide) – PB (Osteo)-1010
• IL-K™ (Anakinra) – PB (RA)-2010
• Asplin™ (Insulin Aspart) – PB (MDT)-3010
• Romi-MultiPlat™ (Romiplostim) – PB (CT)-4020
• Raspa™ (Rasburicase) – PB (CT)-4030
• Ceras-Peg™ (Certolizumab) – PB (RA)-2020
• RapidTEV™ Protease (Recombinant TEV Protease)
• RapidEK™ (Recombinant Enterokinase)
• RapidZymo® (Recombinant Zymolyase)

Quantifiable outcome

• Biomultifold technology achieves expression levels of multigrams of therapeutic proteins per liter of fermentation
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered supporting and core.

• Bioseet (Munich, Germany)supportingChannel Partner/ Reseller/ Distributor · 2 March 2022Paras Biopharmaceuticals joined the Bioseet platform, a virtual marketplace and teamspace for biosimilar and other generic assets to facilitate deals online. The partnership helps expand global outreach of Paras' biosimilar development and partnership offerings. Bioseet's marketplace is described as a global leader in digital biosimilars deal initiation, providing direct access to a growing network of commercialisation partners.
• Pivotal Scientific Limited (PSL) Alliance, UKsupportingGTM or Marketing Partner · 8 September 2020Paras Biopharmaceuticals joined the PSL Alliance, a network of companies operating within the biotechnology market. The alliance provides a platform for manufacturers, suppliers, and distributors to communicate and forge successful working relationships for worldwide reach. Paras joined to reach out to distributors and end users for its recombinant bioprocess enzymes including RapidTEV, RapidEK, and RapidZymo.
• Novozymes (Denmark)coreStrategic or Co-development Partner · 24 November 2015Paras Biopharmaceuticals partnered with Novozymes to use the VELTIS technology for developing an improved once-a-week biobetter version of Teriparatide for osteoporosis treatment. The partnership combined Novozymes' half-life extension technology with Paras' Diabrid NobleCleav technology. The VELTIS technology enables once-weekly, once bi-weekly, or once-monthly peptide or protein dosing, enhancing patient adherence and therapeutic impact.
• Expert Lab Group in the USAsupportingTechnology or Integration · 1 January 2012Paras Biopharmaceuticals collaborated with an expert lab group in the USA for technology development and validation of its expression systems and processes.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Biovian Oy: A Finnish GMP contract development and manufacturing organization specializing in biopharmaceuticals (recombinant proteins, viral vectors, cell therapy), head-quartered in Finland near Paras Biopharmaceuticals. Most directly comparable CDMO peer given overlapping geography, microbial/biologics manufacturing focus, and similar mid-size scale.
• Northway Biotech: Vilnius-based CDMO offering microbial and mammalian biologics development and manufacturing services, plus biosimilar development expertise. Comparable on co-development capabilities, mid-size European CDMO positioning, and a similar microbial/biologics technology focus to Paras.
• AGC Biologics: Global CDMO with microbial and mammalian biologics manufacturing capabilities, offering process development, scale-up, and GMP production. Comparable because microbial expression services and a parallel biosimilar pipeline sit alongside broader CDMO offerings, mirroring Paras' CDMO-plus-biosimilar model.
• Alvotech: Iceland-based biosimilar-focused biopharmaceutical company developing high-quality biosimilars across multiple therapeutic areas. Comparable on biosimilar strategy and partnerships with pharma, overlapping directly with Paras' biosimilar co-development mission.
• Polypeptide Group: Global CDMO specializing in therapeutic peptides — a core product type within Paras' Diabrid® and NobleCleav® technology platforms. Comparable given both firms operate in the peptide contract manufacturing space with proprietary process technology.
• Stada Arzneimittel AG: European pharmaceutical company with a substantial biosimilars franchise (including Epoetin, pegfilgrastim, teriparatide, adalimumab). Overlaps with Paras specifically on the biosimilar co-development and licensing strategy and on addressing affordable-biology markets.

Broad incumbents

• WuXi Biologics: Global market-leading biologics CDMO offering end-to-end development, manufacturing, and quality services across microbial and mammalian platforms. Overlaps with Paras as a biologics CDMO but operates at vastly larger scale, broader technology scope, and global footprint.
• Lonza Biologics: Global CDMO providing mammalian and microbial biologics manufacturing services as part of a broader life-sciences services portfolio. Comparable biologics CDMO offering but with substantially larger bioreactor capacity and broader therapeutic coverage.
• Samsung Biologics: Global large-scale biologics CDMO offering process development, manufacturing, and analytical services. Comparable as a one-stop CDMO alternative for biopharma clients, but with much larger mammalian-cell focus and capacity than Paras.
• BPL (Bio Products Laboratory): UK-based manufacturer of plasma-derived and recombinant biologics. Comparable as a European-headquartered biologics manufacturer with co-development and licensing partnerships aligned to Paras' biosimilar and specialty biologics focus.

Market position

Strengths5 records

Weaknesses6 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/paras-biopharma-finland

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paras Biopharmaceuticals